Clinical need Target hospitals and liver/heart failure centers treating drug-resistant fluid overload, where alfapump and DSR therapies address high-dialysis-like fluid burdens and reduce readmissions.

Financial runway Leverage recent funding to pursue expanded clinical trials, payer discussions, and regional market expansion in Europe, highlighting extended cash runway to support evidence generation and sales cycles.

Strategic partnerships Position with major liver disease and oncology networks, post-acute care providers, and surgical centers to integrate fluid-management solutions into standard of care and perioperative workflows.

KOL & events Engage key opinion leaders active at SIR EDGE, Portal Intervention Symposium, and Liver Connect to accelerate adoption, co-present study results, and secure speaking slots in upcoming conferences.

Market positioning Differentiate from competitors by stressing outpatient and inpatient cost savings, improved patient quality of life, and reduced hospitalizations to justify reimbursement discussions with European payers.